Sign in
Not yet recruitingNo phase

Lung-cOnservative Liquid VEntilation for the Induction of Ultra-Rapid COOLing After Cardiac Arrest

Key facts

Who runs it
ORIXHA
Where
France1 site in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
People taking part
24 people, planned
Started
Mar 2025
Planned end
Mar 2026
Type of study
Interventional
Treatments tested
  • Ultra-rapid therapeutic hypothermia induction by total liquid ventilation
Record updated
29 January 2025

Who can take part

Age
18 years to 84 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 23 criteriaShow less

Who can take part

  • Patient resuscitated after extra- or intra-hospital cardiac arrest, from presumed cardiac or asphyxial origin, regardless of the heart rate initially recorded
  • Age between 18 and 84 years old
  • Time between collapse and return of spontaneous circulation (ROSC) < 60 min
  • Presumption, at the time of inclusion, of a possibility of starting Vent2Cool within a period of less than 120 min after ROSC
  • Unconscious (GCS <8, not able to obey verbal commands after sustained ROSC)
  • Patient affiliated with a social security system (If applicable)
  • Consent of the member of patients' family or that of the trusted person if present and able to understand; otherwise certificate of emergency inclusion in compliance with applicable regulations
  • Vent2Cool must be connected to a standard cuffed ETT of 7.0 mm to 9.0 mm internal diameter for the procedure

Who cannot take part

  • Traumatic cardiac arrest, drowning, exsanguination, or sepsis
  • Need for veno-arterial extracorporeal circulation (Extracorporeal membrane of oxygenation, ECMO) before return of spontaneous circulation (refractory cardiac arrest)
  • Suspicion of intracranial bleeding
  • History of severe Chronic Obstructive Pulmonary Disease (COPD) with long-term home oxygen therapy
  • Acute respiratory pathology (pneumothorax, pleurisy, pneumonia, suspicion of contusion or intra-pulmonary hemorrhage following resuscitation)
  • COVID-19 positive test in case of clinical suspicion and/or epidemic context
  • Women under 50 years old (childbearing age) or for women of >50 years old, a positive pregnancy test (urinary) in case of pregnancy suspicion by the investigator. Possible breastfeeding during the study
  • Conscious patient
  • Patient Ideal Body Weight less than 40 kgs or more than 93 kgs
  • Temperature at admission < 34.0°C
  • One of the following signs at echocardiography at hospital admission:; Acute cor pulmonale, defined by right ventricular enlargement with interventricular septal deviation, associated with a Tricuspid Annular Plane Systolic Excursion (TAPSE) < 12 mm and need for vasopressor agents; Time-velocity integral of subaortic flow < 10 m/s
  • Wrong positioning or damage of the endotracheal tube
  • Excessive mucus in the upper airways
  • Patient presenting at least one of the following criteria in the mechanical ventilation parameters at inclusion:; PEEP > 8 cm H2O; Plateau pressure> 25 cmH2O; Driving pressure> 15cmH2O
  • Patient with at least one of the following criteria at inclusion:; PaO2< 80 mmHg; PaO2 / FiO2< 150 mmHg; PaCO2> 48 mmHg

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 84 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Out-of-hospital cardiac arrest (OHCA) affects over 356,000 individuals annually in the United States, with fewer than 10% surviving to hospital discharge, mirroring statistics from Europe. Post-cardiac arrest syndrome (PCAS), a condition causing multi-organ dysfunction, is a leading cause of mortality despite successful resuscitation efforts. Targeted temperature management (TTM) is recommended for comatose patients post-resuscitation to mitigate PCAS, but optimal temperature targets and cooling methods remain unclear. Experimental studies suggest that therapeutic hypothermia (32-34°C), induced rapidly after resuscitation, may provide significant clinical benefits.

Read full original descriptionShow less

Total liquid ventilation (TLV) with breathable liquids has been proposed to achieve ultra-rapid therapeutic hypothermia (URTH). This approach uses the lungs as a heat exchanger to achieve ultra-rapid cooling while maintaining normal gas exchange. It enables a reduction in core body temperature to the hypothermic range (33.0 ± 0.5°C) within 45 minutes in relevant experimental models.

The OverCool study is an open-label, single-arm, multi-centric pilot trial designed to evaluate the performance and safety of Vent2Cool, a medical device intended to induce ultra-rapid therapeutic hypothermia by TLV in resuscitated cardiac arrest patients. The primary objective is to demonstrate Vent2Cool's ability to achieve a target core temperature of 33.0 ± 0.5°C within 60 minutes from start of procedure in resuscitated patients admitted to the Intensive Care Unit following intra- or extra-hospital cardiac arrest. Secondary objectives include assessing procedural safety, cooling performance, feasibility in emergency settings, clinical outcomes, and the impact on biological markers.

The group in the trial

  • Treatment with Vent2Cool deviceTreatment being tested

    Vent2Cool is to be used to perform induction of Ultra-Rapid Therapeutic Hypothermia for the patients. The hypothermia maintenance and rewarming phases will be performed with an external TTM device as currently used in the investigation centres.

    Treatment: Ultra-rapid therapeutic hypothermia induction by total liquid ventilation

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Criteria questions
Built from NCT06798818, who can take part
Record updated
29 January 2025